349 related articles for article (PubMed ID: 29230799)
21. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and treatment of follicular lymphoma.
Hitz F; Ketterer N; Lohri A; Mey U; Pederiva S; Renner C; Taverna C; Hartmann A; Yeow K; Bodis S; Zucca E
Swiss Med Wkly; 2011; 141():w13247. PubMed ID: 21815111
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).
Schneider T; Rosta A; Losonczy H; Radványi G; Ujj G; Egyed M; Illés Á; Jakucs J; Szerafin L; Gasztonyi Z; Masszi T; Iványi J; Demeter J; Dombi P; Tóth A; Borbényi Z
Pathol Oncol Res; 2018 Apr; 24(2):199-205. PubMed ID: 28432650
[TBL] [Abstract][Full Text] [Related]
24. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
[TBL] [Abstract][Full Text] [Related]
25. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
27. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova J; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Leuk Lymphoma; 2016 May; 57(5):1094-103. PubMed ID: 26293000
[TBL] [Abstract][Full Text] [Related]
28. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
Bech RS; Nielsen KL; Larsen TS; Bentzen HH; Lynggaard LS; Do TH; Braendstrup P; Brady J; Mikhaeel NG; Dybkaer K; Johnsen HE; Jensen P; Bøgsted M; El-Galaly TC
Br J Haematol; 2018 Jul; 182(2):297-301. PubMed ID: 28542714
[No Abstract] [Full Text] [Related]
29. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
Am J Hematol; 2016 Jun; 91(6):E305-7. PubMed ID: 26950187
[No Abstract] [Full Text] [Related]
30. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
[TBL] [Abstract][Full Text] [Related]
32. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and treatment of follicular lymphoma: an update.
Bargetzi M; Baumann R; Cogliatti S; Dietrich PY; Duchosal M; Goede J; Hitz F; Konermann C; Lohri A; Mey U; Novak U; Papachristofilou A; Stenner F; Taverna C; Zander T; Renner C
Swiss Med Wkly; 2018; 148():w14635. PubMed ID: 30044476
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era.
Tamjid B; Mckendrick J; Schwarer A; Doig R; James P; Hosking P; Hawkes EA
Asia Pac J Clin Oncol; 2017 Jun; 13(3):226-233. PubMed ID: 28004881
[TBL] [Abstract][Full Text] [Related]
36. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
37. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
[TBL] [Abstract][Full Text] [Related]
38. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
39. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]